Why don't other companies undercut Gland's (cost+profit margin+profit share) model especially when they enjoy such high margins? Does Gland deal in products where competition doesn't exist?
Also, isn't Gland expensive currently? I feel all ratios stop me from purchasing it, high PE, high PB, high Price/Sales, low CFO/EBITDA. Wanted to know your opinion on valuations given it leaves very less margin of safety compared to other opportunities present in the pharma industry.
PS: Love your Journal & insights. Thank you for the content.
Why don't other companies undercut Gland's (cost+profit margin+profit share) model especially when they enjoy such high margins? Does Gland deal in products where competition doesn't exist?
Also, isn't Gland expensive currently? I feel all ratios stop me from purchasing it, high PE, high PB, high Price/Sales, low CFO/EBITDA. Wanted to know your opinion on valuations given it leaves very less margin of safety compared to other opportunities present in the pharma industry.
PS: Love your Journal & insights. Thank you for the content.